Skip to main content
TipRanks
Go Ultimate75% OFF

AdAlta Ltd. (1AD) AI Stock Analysis

8 Followers
AU:1AD

AdAlta Ltd.

(ASX:1AD)

Select Model
Rating:37Underperform
Price Target:AUD 0.01▲(350.00% Upside)
Action:reiterated
Date:08/22/26

The overall score is at the minimum, reflecting a company in severe distress. The complete loss of revenue and ongoing cash burn are the most significant risks, leaving the company in a precarious financial position. The cleaned-up balance sheet is a minor positive but is overshadowed by the lack of income and minimal asset base. The absence of technical data and negative valuation metrics reinforce the critical risk profile.

Positive Factors
Debt eliminationEliminating debt reduces interest obligations and lender dependence, giving AdAlta greater financial flexibility while it develops its pipeline. However, the benefit is limited because the company still has weak cash generation and may require external funding.
Negative Factors
Revenue deteriorationThe sustained decline to zero revenue indicates that AdAlta currently lacks a dependable commercial income stream. Without recurring product, licensing, or partnership revenue, funding for research and operations remains dependent on uncertain external capital.

AdAlta Ltd. (1AD) vs. iShares MSCI Australia ETF (EWA)

Not enough price history over this period.

Market Cap
AUD 1.52M
Dividend Yield
―
Average Volume (3M)
―
Price to Earnings (P/E)
-0.9
Beta (1Y)
0.98
Revenue Growth
―
EPS Growth
62.90%
Country
Australia
Employees
2
Sector
Healthcare
Sector Strength
51
Industry
Biotechnology

AdAlta Ltd. Business Overview & Revenue Model

Company Description

AdAlta Limited is an Australian-based clinical-stage biotechnology company dedicated to the discovery and development of innovative protein therapeutics. Its leading investigational i-body drug candidate, AD-214, is presently in Phase I clinical tria...

How the Company Makes Money

null

AdAlta Ltd. Financial Statement Overview

Summary

Financial health is critically weak. Revenue has collapsed to zero, net losses persist, and cash burn continues despite a reduced rate. The cleaned-up balance sheet with zero debt is the only positive, but minimal assets and equity provide no buffer against ongoing losses.

Income Statement

8Very Negative

Balance Sheet

30Negative

Cash Flow

25Negative
Financial statement breakdown
BreakdownTTMJun 2026Jun 2025Jun 2024Jun 2023Jun 2022
Income Statement
Total Revenue00677.01K1.74M3.47M2.75M
Gross Profit00457.50K1.51M3.44M2.49M
EBITDA-4.80M-4.80M-4.38M-5.26M-7.58M-7.31M
Net Income-4.68M-4.68M-4.50M-5.38M-4.85M-6.06M
Balance Sheet
Total Assets1.72M1.72M2.14M5.57M7.73M10.65M
Cash, Cash Equivalents and Short-Term Investments1.28M1.28M1.31M3.13M4.79M8.66M
Total Debt001.77M2.70M4.01M4.00M
Total Liabilities1.35M1.35M2.74M3.54M5.82M5.27M
Stockholders Equity370.17K370.17K-598.24K2.03M1.91M5.38M
Cash Flow
Free Cash Flow-4.44M-4.44M-2.94M-5.32M-5.13M-4.11M
Operating Cash Flow-4.44M-4.44M-2.94M-5.26M-5.13M-4.09M
Investing Cash Flow00109.61K-62.40K-2,126-25.23K
Financing Cash Flow4.42M4.42M999.06K3.67M1.27M7.02M

AdAlta Ltd. Peers Comparison

Overall Rating

UnderperformOutperform
Sector (51)

Financial Indicators

AU:1AD against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
AU:NEUAU:NEU76OutperformAUD 2.79B133.996.03%0.68%-68.00%-86.31%
Sector *51Neutral$7.86B-0.30-43.30%2.27%22.53%-2.21%
AU:IMMAU:IMM50NeutralAUD 38.33M-0.47-98.86%――-27.73%
AU:RCEAU:RCE46NeutralAUD 114.72M-7.3384.67%――42.51%
AU:CMBAU:CMB39UnderperformAUD 10.30M-1.39-247.44%―-4.24%33.39%
AU:1ADAU:1AD37UnderperformAUD 6.42M-0.87-6182.61%――62.90%

* Healthcare Sector Average

Performance Comparison

-50%0%50%AU:NEUAU:IMMAU:CMBAU:RCEDec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
AU:1AD and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
AU:1ADAdAlta Ltd.―――
AU:NEUNeuren Pharmaceuticals Limited22.013.9922.16%
AU:IMMImmutep Ltd0.03-0.23-90.00%
AU:CMBRegeneus Ltd.0.35-0.17-32.69%
AU:RCERecce Pharmaceuticals Ltd.0.38-0.05-11.76%

AdAlta Ltd. Corporate Events

AdAlta updates ASX corporate governance disclosures for 2026

Aug 21, 2026

AdAlta has lodged its updated corporate governance statement for the year ended 30 June 2026, confirming that the document is available on its website and has been approved by the board as at 20 August 2026. The company’s accompanying Appendix 4G fil...

AdAlta Releases Annual Report for Year Ended 30 June 2026

Aug 21, 2026

AdAlta Limited has released its annual report for the year ended 30 June 2026, outlining its corporate directory, directors’ report, financial statements, and auditor’s report. The document provides a comprehensive overview of the company’s governanc...

AdAlta posts wider annual loss and flags going concern uncertainty

Aug 21, 2026

AdAlta Limited reported a net loss after tax of $4.68 million for the year ended 30 June 2026, a 4% increase on the prior year’s $4.50 million loss, and did not declare any dividends for the period. Net tangible assets per share improved to $0.01 fro...

AdAlta outlines global immunotherapy ambitions while flagging investment risks

Aug 13, 2026

AdAlta Limited has released an investor presentation outlining its strategy to commercialise life-saving cellular immunotherapies under an “East to West” approach, signalling ambitions to translate its research into marketed therapies across multiple...

AdAlta’s EW-001 CAR-T Shows Promising Survival and Response in Advanced Mesothelioma

Aug 9, 2026

AdAlta reported that all five mesothelioma patients who remained on its Chinese investigator-initiated trial as of March 2026 were still alive and on study in July, extending evidence of sustained survival. Among 10 patients treated at higher EW-001...

AdAlta Posts Landmark Long-Term Responses in Mesothelioma CAR-T Trial

Aug 4, 2026

AdAlta has reported a major clinical milestone in its ongoing investigator-initiated trial of EW-001 in advanced mesothelioma, with the first patient to achieve complete tumour clearance remaining alive and cancer-free two years after a single dose....

AdAlta Advances EW-001 CAR-T Program and AI-Driven East-to-West Strategy

Jul 29, 2026

AdAlta has strengthened its position in solid tumour cell therapies by completing its initial US$1 million milestone investment in EW-001, securing rights to develop the CAR-T treatment outside Greater China and obtaining key clinical and manufacturi...

AdAlta Seeks ASX Quotation for Major New Share and Option Issue

Jul 1, 2026

AdAlta Limited has applied for quotation on the ASX of 37,500,000 new ordinary fully paid shares and 168,750,000 options expiring in June 2028. The issuance, lodged under an Appendix 2A, significantly increases the company’s quoted securities base an...

AdAlta Seeks ASX Quotation for Nearly 265 Million New Securities

Jul 1, 2026

AdAlta Ltd. has applied to the ASX for quotation of 198,750,012 new ordinary fully paid shares and 66,250,001 options expiring in June 2028, all issued on 2 July 2026. The move significantly increases the company’s listed securities base, signalling...

AdAlta expands AI-driven drug development with Oktopi collaboration

Jul 1, 2026

AdAlta Limited has entered a strategic collaboration with Oktopi to deploy its AI-enabled, software-as-a-service knowledge platform across AdAlta’s medicine development programs, enhancing how the company plans research, identifies critical questions...

AdAlta Issues 319.9 Million New Shares in Private Placement

Jun 25, 2026

AdAlta Limited has issued 319,937,238 new fully paid ordinary shares at $0.004 each to sophisticated investors under a private placement previously announced to the market. The company has lodged an application for quotation of these shares and confi...

AdAlta seeks ASX quotation for major new share and option issue

Jun 25, 2026

AdAlta Ltd. has applied to the ASX for quotation of 319,937,238 ordinary fully paid shares under code 1AD and 142,083,332 options expiring 3 June 2028 under code 1ADO, with an issue date of 25 June 2026. The large volume of new shares and options bei...

AdAlta targets sophisticated investors with speculative ASX-listed options offer

May 24, 2026

AdAlta Limited has issued a target market determination for a new series of quoted options, each allowing holders to acquire one fully paid ordinary share, to be offered under a prospectus dated 22 May 2026. The options, aimed at sophisticated and pr...

AdAlta files prospectus for options linked to A$2.5m placement to fund solid cancer immunotherapy push

May 24, 2026

AdAlta Limited, a Melbourne-based clinical-stage biotech, specialises in cellular immunotherapies for solid tumours and leverages an ‘East to West’ model that links Asian T cell therapy innovation with Western regulatory and commercial pathways. Its...

AdAlta hires cell therapy specialists to steer FDA path for mesothelioma CAR-T

May 24, 2026

AdAlta has engaged specialist consultancy Dark Horse Consulting Group to guide regulatory interactions with the US Food and Drug Administration for its lead CAR-T therapy, BZDS1901, as it prepares for an Australian Phase 1 clinical trial. The move ai...

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Aug 22, 2026